Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GK01 in Advanced Solid Tumors
NCT07412665Phase 1Not yet recruiting
- Sponsor
- Beijing Geek Gene Technology
- Start
- Jun 2026
- Primary completion
- Mar 2027
- Modality
- Tumor-Infiltrating Lymphocytes (TILs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GK01 cell injection in solid tumor, sponsored by Beijing Geek Gene Technology. Primary endpoint: Safety and Tolerability at 2 years. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
GK01 cell injection
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07412665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07412665.